Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma

Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * The patient has an WHO score ≤ 3 * The patient's estimated life expectancy is more than 3 months. * Patient with histologically proven diagnosis of glioblastoma. * Patient presenting with tumor progression on morphological MRI confirmed by a multidisciplinary committee. * Patient with a unilateral supratentorial target lesion upon inclusion to establish a tumor region of interest (ROI) zone and an equivalent ROI zone in contralateral healthy tissue. * Patient progressing after radiotherapy and at least one line of chemotherapy with TEMODAL * Patient in whom treatment with Bevacizumab monotherapy has been validated by a multidisciplinary committee. Exclusion Criteria: * The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Pregnant or breast feeding patients * Hypersensitivity to iodinated contrast media and creatinine clearance less than 60 ml / minute.